Conference call regarding Elekta’s Interim Report for May-October 2012/13

Elekta will publish its interim report for May-October 2012/13 on December 4 as per:

  • The report will be published at 07.30 CET.
  • Elekta will host a telephone conference at 10.00-11.00 CET with Tomas Puusepp, President and CEO, and Håkan Bergström, CFO.

To take part in the conference call, please dial in about five minutes in advance, use the telephone numbers below and the access code 925300

  • UK dial-in number: +44 (0)20 7162 0077
  • US dial-in number: + 1 877 491 0064
  • Swedish dial-in number: +46 (0)8 5052 0110

The telephone conference will be broadcasted live online (audio only and without the possibility to ask questions). Please use the link: http://webeventservices.reg.meeting-stream.com/71577_elekta

******

For further information, please contact:
Johan Andersson Melbi, Director Investor Relations, Elekta AB.
Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com.

About Elekta
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.

About Us

For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.

Subscribe

Documents & Links